Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cervical fusion & disc arthroplasty cases in Ohio: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (210 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 49 | 2,198 | 47% |
| 2020 | 32 | 1,765 | 50% |
| 2021 | 29 | 1,770 | 53% |
| 2022 | 28 | 1,707 | 56% |
| 2023 | 33 | 1,835 | 58% |
| 2024 | 25 | 1,738 | 60% |
| 2025 from claims | – | 1,849 1,697–1,956 | 61% |
| 2026 forecast | – | 1,898 1,670–2,190 | 61% |
| 2027 forecast | – | 1,905 1,628–2,270 | 61% |
| 2028 forecast | – | 1,911 1,595–2,340 | 61% |
| 2029 forecast | – | 1,917 1,566–2,405 | 62% |
| 2030 forecast | – | 1,924 1,541–2,465 | 62% |
ACDF, posterior cervical fusion, cervical total disc replacement. Professional codes (what the surgeon bills): CPT 22551, 22600, 22856; the hospital bills MS-DRG 471, 472, 473, 429, 430.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 52% of the cases CMS names in Ohio; 19 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 62% inpatient hospital, 33% hospital outpatient, 5% surgery center. The share outside the hospital has moved +2 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 28 | 1,515−7.1%/yr | −7.1%/yr | 1.1 | 2% | 1,670 in 2030+1.6%/yr |
| Michigan | 24 | 1,338−6.2%/yr | −6.2%/yr | 1.5 | 3% | 1,110 in 2030−3%/yr |
| Missouri | 25 | 1,166−5.8%/yr | −5.8%/yr | 1.8 | 1% | 1,250 in 2030+1.1%/yr |
| Indiana | 21 | 997−4.8%/yr | −4.8%/yr | 1.4 | 3% | 960 in 2030−0.6%/yr |
| Minnesota | 9 | 723−4.6%/yr | −4.6%/yr | 1.5 | 0% | 840 in 2030+2.4%/yr |
| Kansas | 11 | 616−1.8%/yr | −1.8%/yr | 1.5 | 0% | 710 in 2030+2.5%/yr |
| Wisconsin | 3 | 479−5.3%/yr | −5.3%/yr | 0.8 | 4% | 730 in 2030+7.3%/yr |
| Iowa | 9 | 408+2.6%/yr | +2.6%/yr | 0.9 | 3% | 500 in 2030+3.4%/yr |
| Nebraska | 8 | 406−2.1%/yr | −2.1%/yr | 1.5 | 6% | 480 in 2030+2.7%/yr |
| South Dakota | 4 | 201−1.4%/yr | −1.4%/yr | 1.5 | 0% | 270 in 2030+4.8%/yr |
| North Dakota | 3 | 152−5.1%/yr | −5.1%/yr | 1.5 | 0% | 160 in 2030+0.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 114 | 4,105−5.1%/yr | −5.1%/yr | 3.61.2× | 8% | 4,010 in 2030−0.4%/yr |
| Lumbar fusion | 90 | 3,677−2.1%/yr | −2.1%/yr | 3.21.2× | 1% | 4,120 in 2030+1.9%/yr |
| Kyphoplasty & vertebroplasty | 15 | 1,537−7.3%/yr | −7.3%/yr | 1.41.0× | 1% | 1,360 in 2030−2.1%/yr |
| SI joint fusion | 7 | 367+22%/yr | +22%/yr | 0.31.6× | 11% | 610 in 2030+8.7%/yr |
Cervical fusion & disc arthroplasty in every state, and its device makers · Every procedure market in Ohio · Every state · Compare with Illinois
Medtronic leads with 31% of company spending on these surgeons in 2025, −31 pts on 2024.
In 2025, 14 companies reported engagement with Ohio’s surgeons worth $215K in consulting, speaking, meals and travel tied to these products, about $8,591 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 69 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.